Global Human Platelet Lysate Market (2018-2025)-GMI Research Global Human Platelet Lysate Market (2018-2025)-GM | страница 2

Download Sample Brochure : https://www.gmiresearch.com/sample-research-
report.php?rid=131
Rising adoption of human platelet lysate in place of fetal bovine serum, funding
for life science research and investments, adoption of advanced blood collection
and processing technology in emerging countries are the major drivers expected
to positively influence the growth of global human platelet lysate market in the
coming years. In addition, increasing research & development activities and
surging demand for animal-free serum media are likely to spur the growth of
global human platelet lysate market. Emergence of innovative technologies,
such as stem cell and cell-based therapeutics are also predicted to increase
demand for human platelet lysate. However, price constraints, lack of awareness
and availability of alternative products may hamper the growth of human platelet
lysate market across the globe during the forecast period.
The cell culture industry paradigm tends to shift from bovine to animal-free
serum, thus, regional governments are adopting European guidelines for
culturing the media for any therapeutic products. This shift is likely to help
human platelet lysate to become an attractive alternative to the serum
supplement in area of cell culturing, which is expected to increase demand for
human platelet lysate during the forecast period. The global human platelet
lysate market has tremendous growth potential owing to increasing regulatory
approvals for vaccine production via cell culture-based and well-developed
research centers and institutes.
Various notable players operating in the market, include Merck KGaA, Compass
Biomedical Inc., Macopharma SA, Cook Medical (Cook Regentec), Mill Creek Life
Sciences Llc., Stemcell Technologies Inc., Zen-Bio, Inc., Sclavo Diagnostics
International Srl, Life Science Production, and Trinova Biochem Gmbh, among
others. Most of the companies are focusing on new batch technology for the